Saturday February 24th 2018

Cost-Effectiveness Analysis of Peginterferon Beta-1a In Italian Relapsing Remitting Multiple Sclerosis Management

Peginterferon beta-1a is indicated for the treatment of adult relapsing remitting multiple sclerosis (RRMS) patients. The efficacy and safety of subcutaneous (SC) peginterferon beta-1a (PEGIFN beta-1a) was demonstrated in the randomised double blind Phase 3 placebo-controlled ADVANCE trial. We assessed the cost-effectiveness of PEGIFN beta-1a compared with other injectable first-line RRMS treatments in Italy. (Source: Value in Health)

See more here: 

Cost-Effectiveness Analysis of Peginterferon Beta-1a In Italian Relapsing Remitting Multiple Sclerosis Management

Leave a Comment

More from category

Multiple sclerosis: Skin cells may help to repair nerve damage
Multiple sclerosis: Skin cells may help to repair nerve damage

Researchers could be on the verge of a new treatment for multiple sclerosis; they reveal how transplanting neural stem [Read More]

Medical News Today: Multiple sclerosis: Skin cells may help to repair nerve damage
Medical News Today: Multiple sclerosis: Skin cells may help to repair nerve damage

Researchers could be on the verge of a new treatment for multiple sclerosis; they reveal how transplanting neural stem [Read More]

Researchers discover how the body skillfully extinguishes inflammation
Researchers discover how the body skillfully extinguishes inflammation

Inflammation needs energy An important source for this energy is oxygen, which is indispensable for the cells of the [Read More]

MS patients who feel stigmatized more likely to suffer from depression
MS patients who feel stigmatized more likely to suffer from depression

People with Multiple Sclerosis -- MS -- who feel stigmatized are more likely to suffer from depression, according to [Read More]

Stigma increases risk of depression for people with Multiple Sclerosis
Stigma increases risk of depression for people with Multiple Sclerosis

(Penn State) People with Multiple Sclerosis -- MS -- who feel stigmatized are more likely to suffer from depression, [Read More]